the-lancet-oncology
The Lancet Oncology (the-lancet-oncology)
Journal positioning
The Lancet Oncology is a flagship specialty title in the Lancet family and one of the world's most prestigious clinical oncology journals, published by Elsevier. It publishes practice-changing cancer clinical trials, oncology policy, cancer epidemiology, and translational cancer research that is directly relevant to the clinical management of cancer at a global level. The journal maintains the Lancet family's editorial standards: rigorous trial registration, CONSORT compliance, equity and global-health consciousness, and a bias toward findings that shift oncology practice or inform cancer policy. Studies that are methodologically sound but incremental—small improvements in surrogate endpoints, single-arm studies without historical context, or descriptive epidemiology without actionable implications—are unlikely to succeed here.
This skill is a fit / venue-selection / re-framing tool. It does not replace the journal's current official submission guidelines. Before submitting, re-check the live author instructions on the Lancet/Elsevier site or submission system.
When to trigger
- The author names The Lancet Oncology as the target venue for a phase III cancer trial, cancer epidemiology analysis, or oncology-policy paper.
- A cancer clinical trial has results that could change standard of care across a patient population at international scale.
- A cancer-burden or cancer-control analysis has policy implications for global or regional oncology systems.
- The author needs The Lancet Oncology's desk-reject risks and credible alternatives before submitting.